Diligence memo · auto-generated · as of July 2, 2026
StimuSIL, Inc.
StimuSIL, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
StimuSIL, Inc. operates in Biotechnology, based in WILMINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
StimuSIL, Inc. has raised $2.3M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.1M on 2024-04-08.
Most recent recorded round closed around 2024-12-31.
Valuation (modeled)modeled
Provath models StimuSIL, Inc. at approximately $2.2M (range $432K–$5.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.15× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 18 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 1.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 30% of Biotechnology peers (4293 compared).
Modeled value ranks above 6% of those peers.
Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.